Funding led by AMR Action Fund, Illumina Ventures, and Omnimed Capital supports U.S. clinical trial and 510(k) submission for rapid Pneumonia identification and antibiotic susceptibility testing (ID/AST) panel

AUSTIN, Texas, November 18, 2025: Pattern Bioscience, an innovator in rapid diagnostic technologies for bacterial infections, announced it has raised $43 million in Series D financing, led by AMR Action Fund, Illumina Ventures, and Omnimed Capital. The funding will support completion of a U.S. multi-center clinical trial and regulatory submission of the company’s first test, the Pneumonia ID/AST Panel, designed to diagnose critically ill patients with suspected pneumonia.

Delayed antibiotic guidance for critically ill patients with pneumonia drives higher mortality, prolonged hospitalization, and the spread of antimicrobial resistance. Faster diagnostics are urgently needed to enable targeted therapy earlier in the infection course. Pattern’s single-cell microbiology technology addresses this need by analyzing bacterial cells directly from patient specimens, delivering rapid pathogen identification and phenotypic antimicrobial susceptibility results in hours instead of the days currently required for culture-based testing.

“I have partnered with Pattern since 2018 and have seen this team turn a bold idea into a clinically viable platform,” said Greg Wood, Managing Director at Omnimed Capital. “Reaching clinical validation for the Pneumonia ID/AST Panel is a pivotal step toward delivering rapid, culture-free phenotypic susceptibility results that can improve patient outcomes and reduce healthcare costs.”

Pattern’s Pneumonia ID/AST Panel has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) and is also receiving non-dilutive support through a Biomedical Advanced Research and Development Authority (BARDA) contract valued at up to $40.9 million.  The platform is designed to support a broad menu of tests, including high-value ID/AST assays across respiratory, urinary tract, and bloodstream infections. After completing two multi-site external studies with thousands of bronchoalveolar lavage (BAL) and endotracheal aspirate (ETA) specimens tested, Pattern is now entering clinical validation.

“This financing underscores the strong confidence in Pattern’s approach and momentum as we advance into clinical validation,” said Carey-Ann Burnham, PhD, Chief Executive Officer of Pattern Bioscience. “We have aligned with the FDA on our analytical and clinical validation studies, and we feel the urgency to deliver faster treatment guidance to critically ill patients who cannot afford to wait days for effective therapy.”

“With antimicrobial resistance contributing to more than 4.5 million deaths annually, it is imperative that we provide clinicians with the tools they need to rapidly diagnose infections and identify the antibiotics that will provide the greatest patient benefit,” said Carly Levine, PhD, Senior Associate at the AMR Action Fund. “We are pleased to support the team at Pattern as they advance their platform through clinical testing and toward regulatory review.”

Proceeds from the financing will be used to complete the U.S. multi-center clinical trial, submit a 510(k) for the Pneumonia ID/AST Panel, and prepare for first U.S. commercial launch following regulatory clearance.

About Pattern Bioscience
Pattern Bioscience aims to save lives by transforming how bacterial infections are diagnosed and to improve global health by reducing the burden of antibiotic resistance. Its single-cell microbiology technology is designed to deliver clinically actionable results in hours, compared with the days required for traditional culture-based methods. Pattern Bioscience is a privately held company based in Austin, Texas. For more information, visit pattern.bio.

Research reported in this press release received support from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to supporting early-stage antibacterial research and develop to address the rising threat of drug-resistant bacteria. 

Media Contact
Kyle Fieleke
kyle@pattern.bio